Category: Pharmaceutical

Categories
Pharmaceutical

Sales of Stent Graft Balloon Catheter In Cardiac Catheterization Laboratories Is Surged with a CAGR of 5.1% By 2022

The global demand for stent graft balloon catheter will register a healthy expansion during 2017 to 2022. Revenues from the market are expected to surpass US$ 1,000 Mn by the end of 2022.

Usually utilized in bypass graft surgery as well as balloon angioplasty, stent graft balloon catheters prevent risks concerning occurrence of re-narrowing in patients undergoing angioplasty, and risks related to abrupt artery closure. Owing to these advantages offered by stent graft balloon catheters, their demand is witnessing a rise. A gradual evolution has been observed in the stent graft balloon catheter market, from the simple stents to modification of balloon stent catheters. Since recent past, there has been a surge in hospital admissions caused by increasing cases of atherosclerosis, and soaring prevalence of CAD – coronary artery disease globally.

Numerous developments have been realized in technology of balloon catheters, along with the hike in healthcare expenditure. These factors are expected to augment growth of the market. In contrast, high prices of angioplasty procedures has become a problem for population across developing and underdeveloped economies. This might act as an impeding factor for the market growth.

To remain ‘ahead’ of your competitors, request a sample

https://www.factmr.com/connectus/sample?flag=S&rep_id=149

Growth of the global stent graft balloon catheter market has been highly favored by the advent of drug eluting balloons. In addition, shifting preferences towards using balloons with drug delivery, and helping to deliver medications at local sites, has deemed them to be effective substitutes for administering drugs intravenously. Various new products developed are being approved for treatment of vascular diseases. For instance – recently, the FDA has approved use of expandable balloon stent graft introduced by the W.L. Gore & Associates to treat peripheral artery disease. Moreover, technology advancements in the stent graft balloon catheters, coupled with increasing awareness about angioplasty, and sophisticated healthcare infrastructure in developed economies are further poised to drive the market growth in the near future.

For critical insights on this market, request for methodology here-

https://www.factmr.com/connectus/sample?flag=RM&rep_id=149

Market Taxonomy

Indication
  • Coronary Artery Disease
  • Peripheral Vascular Disease
End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories
Raw Material
  • Polyurethane
  • Nylon
  • Others

Speak To Research Analyst For Detailed Insights:

https://www.factmr.com/connectus/sample?flag=AE&rep_id=149

9 Key Estimations from Fact.MR’s Report on the Global Stent Graft Balloon Catheter Market

  1. Based on raw material, sales of polyurethane for producing stent graft balloon catheters will register a steady expansion, while sales of nylon are estimated to register a sluggish growth through 2022.
  2. Cardiac catheterization laboratories are anticipated to become the fastest growing end-users in the global stent graft balloon catheter market.
  3. Ambulatory surgical centres are expected to be the least lucrative end-users of stent graft balloon catheters.
  4. Hospitals will continue to be the largest end-user segment, with sales poised to reach nearly US$ 900 Mn by 2022-end.
  5. Sales of stent graft balloon catheters for coronary artery disease indication are projected to account for over two-third share of the market over the forecast period, in terms of revenues.
  6. Demand for stent graft balloon catheters from peripheral vascular disease indication segment will remain sluggish in the market.
  7. Although, the market in Middle East & Africa (MEA) is expected to register a sluggish expansion, sales of stent graft balloon catheter in this region are estimated to gain an uptick by 2022-end.
  8. Europe will continue to be the largest market for stent graft balloon catheter, with sales projected to exceed US$ 400 Mn in revenues by 2022-end.Key players contributing to the growth of the market

    Meril Life Sciences Pvt. Ltd. Abbott Laboratories, Hexacath, Cardionovum GmbH, Jotech GmbH, MicroPort Scientific Corporation, Boston Scientific Corporation, Terumo Corporation, Cook Medical INC, B. Braun Melsungen AG, Cordis Corporation, and Medtronic Plc.

For More Insights

https://www.biospace.com/article/unhealthy-lifestyle-habits-and-improving-awareness-about-new-therapeutics-are-two-key-factors-driving-osteopenia-treatment-market-growth-notes-fact-mr/

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Categories
Pharmaceutical

What are the Factors Spearheading the Growth of Citicoline In US : Check Latest Report

The Fact.MR report tracks the citicoline market for the period 2018-2028. According to the report, the Demand for citicoline is projected to grow at 8.5% CAGR through 2028.

The Growth of Citicoline Market is huge. The Market study analyzes each market player encompassed in the market study as per its market share, production footprint, current launches, agreements, ongoing R&D projects, and market strategies. SWOT analysis has been performed in the market study to investigate the strengths, weaknesses, opportunities and threats of each player.

According to a recent research by Fact.MR, the citicoline market is estimated to surpass US$ 550 million in 2019. Citicoline demand is driven by a range of factors, notably increasing geriatric population and growing use among eSports players. The study offers in-depth and incisive insights on key factors influencing the global demand for citicoline.

To remain ‘ahead’ of your competitors, request for a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=2868

Supplement Consumption Among eSports Players: A Lucrative Opportunity

Growing popularity and increasing investments in electronic Sports is helping the market go mainstream which, in turn, is opening an assortment of opportunities for various industries. Players participating in eSports tournaments are seeking cognitive enhancing supplements which can help them concentrate, plot strategies, and improve working memory.

Additionally, a ban on the use of other nootropics such as Ritalin and Adderall in eSports leagues is creating demand for ‘permissible’ supplements. Citicoline’s negligible toxicity and its organic nature is making it an appealing prospect for eSports players. With regulations allowing the use of citicoline in functional food and supplements, manufacturers are increasingly focusing towards including the compound in their products to capitalize on the bolstering demand for cognitive-enhancing supplements in eSports.

For critical insights on this market, request for methodology here –  https://www.factmr.com/connectus/sample?flag=RM&rep_id=2868

citicoline market taxonomy

Citicoline’s Role in Ischemic Stroke Treatment Creating Opportunities

The adverse and often fatal impact of ischemic stroke on human health, coupled with increasing prevalence is bolstering demand for effective treatment of the condition. According to WHO, stroke is the second leading cause of death in the world and the third leading cause of disabilities in adults.

Additionally, the lack of a standard procedure of treatment for different ischemic stroke patients is influencing healthcare researchers to focus on the development of acute therapy for all patients. According to Fact.MR’s study, citicoline is being viewed as a potential treatment option by researchers and healthcare providers. These factors are vital to citicoline market growth and are expected propel proliferation during the forecast period.

The study opines that citicoline demand is also likely to be influenced by its role in treatment of brain injuries. Studies suggest treatment of patients with citicoline has been beneficial in reducing headaches, dizziness, tinnitus, and in substantially relieving motor, cognitive, and mental symptoms.

Read More Trending Reports of Fact.MR-

https://www.prnewswire.com/news-releases/respiratory-virus-vaccines-rd-focused-on-covid-19-efforts-factmr-301230897.html

These developments are further driving researchers towards testing its potential use in treatment for pervasive developmental disorders such as atypical autism, Asperger Syndrome, and autism. Intensifying clinical trials and research and developmental activities in the area are expected to open new and lucrative opportunities for companies in the citicoline market.

Increasing Demand for Memory-boosting Supplements for Elderly to Bolster Market Growth

The growth in the geriatric population around the world is expected to continue with the Population Reference Bureau (PRB) estimating the number of people aged over 65 to account for 16 percent of the world population by 2050. Citicoline finds widespread usage in the production of supplements for enhancing cognition in the elderly.

In addition, intensifying clinical trials towards improving citicoline efficacy through its synergy with other chemicals is another vital factor estimated to drive market growth. Fact.MR opines that advancements in tablet manufacturing will bolster production of highly effective supplements, with sales of citicoline tablets estimated to reach nearly US$ 235 million in 2019.

Full Access of this Exclusive Report is Available at-
https://www.factmr.com/checkout/2868

citicoline market snapshot

Key findings of the report:

  • Prominent manufacturers, raw material suppliers, equipment providers, traders, and distributors in the market.
  • In-depth analysis of important market segments, market potential, impacting trends, and challenges.
  • Critical examination of the strengths, weaknesses, opportunities and threats of each player.
  • Extensive investigation of the effects of the growth of relevant industries.
  • Accurate data regarding the future prospects of the during the forecast period.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Categories
Pharmaceutical

Sales of eCOA, eSource, & Clinical Trials are Envisaged to Register a CAGR of ~14% through 2029

Fact.MR study provides the long-term outlook of the eCOA, eSource, & clinical trials market for 2019 to 2029. The sales of eCOA, eSource, & clinical trials are envisaged to register a CAGR of ~14% through 2029.

The latest Fact.MR study indicates healthcare facilities, contract research organizations, and educational & research institutes collectively spent ~US$ 1,950 Mn on eCOA, eSource and clinical trials solutions in 2018. The demand for eCOA,eSource & clinical trials is envisaged to witness substantial traction through 2019, with gains primarily driven by the growing penetration of digitization in healthcare sector and substantial increase in pharma spending on clinical trials.

Click HERE To get a SAMPLE (Including Full TOC, Table & Figures) at https://www.factmr.com/connectus/sample?flag=S&rep_id=4042

Rapidly expanding deployment of clinical trial solutions, which contributed to ~40% of the total spending on eCOA, eSource, and clinical trials in 2018, will continue to appeal a widening bandwidth of institutions through 2029, says the report.

clinical trials industry structure

Market Segmentation

Global ECOA, eSource & Clinical Trials Spending 2014-2018 and Forecast 2019-2029, by Solution Type 

eCOA  (Electronic clinical Outcome assessment)
ePROs (Patient Reported Outcomes)
ClinROs (Clinician Reported Outcomes)
ObsROs (Observer reported Outcomes)
PerfOs (Performance Outcomes)
eSource
Clinical Trials Solutions
Clinical Data Management Systems (CDMS)
Clinical Trial Management Systems (CTMS)
Randomization and Trial Supply Management Systems (RTMS)
Trail Planning and Safety Solutions
Electronic Data Capture (EDC)

Global ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029, by Deployment

  • Licensed Enterprise (On Premise)
  • Cloud-based (SaaS)

Global ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029, by End User

Contract Research Organizations
Hospitals & Other Healthcare Facilities
Pharmaceutical/Biotechnology/Medical Devices Companies
Educational & Research Institutes

Global ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029, by Region

North America
Latin America
Europe
Middle East and Africa (MEA)
East Asia
South Asia
Oceania

Need more information about Report Methodology? Click here- 

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4042

Spending on eCOA Set to Quadruple

The Fact.MR study opines that though the deployment of clinical trial solutions overshadowed the use of Electronic Clinical Outcome Assessment (eCOA), eSource, and EDA in 2018, the market is envisaged to witness a range of changes during the foreseeable period. The growing penetration of Bring Your Own Device (BYOD) trend in clinical trials is highly likely to pace up the use of eCOAs, such as ePROS, ClinROs, ObsROs, and PerfORs across a wide range of pharmaceutical companies and research facilities.

eCOAs is envisaged to hold ~45% of the overall spending share by the end of 2029, in line with the growing use of smartphones and tablets to seamlessly collect clinical data for analysis. Additionally, reduced cost and high scalability of eCOA are the primary determinants that continue to push its adoption during clinical trials, which is envisaged to contribute significantly to the growth of the eCOA, eSource & clinical trials market

Stakeholders Eyeing Opportunities through Collaborations

As the healthcare sector delves deeper into advanced technology, a large number of companies have formulated unique strategies to remain unaffected by the curve of change. Several pharmaceutical companies, research organizations, and CROs have placed their focus on collaborations, while they embrace digitization to create patient-centric experiences. For instance, Signant Health has launched a partner program to collaborate with Clinical Research Organizations (CROs) that are dedicated towards improving clinical trials using patient-centric technology.

Additionally, Iqvia has recently launched a novel eCOA cloud based technology platform to quantify the patient experience, while increasing efficiency and reducing timelines at the same time.

Growing Demand for Clinical Trials to Underpin Spending of Emerging Regions

As per the Fact.MR study, the increasing prevalence of various chronic infectious diseases has led to a dire unmet need for efficient clinical trials in developing countries. Moreover the rising medical expense in these regions, which can be attributed to the fact that private hospitals are the key healthcare providers herein, continue to fuel clinical trial participation in developing countries. This, coupled with the growing awareness about the cost and efficiency benefits of using eCOA, eSource & clinical trial solutions for conducting clinic trials, and comparatively lenient regulatory framework are likely to add to the lucrativeness of developing countries, such as China and India for market players.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4042

Developed Regions Spearhead in Clinical Trials Deployment Rate

The rapidly advancing healthcare infrastructure, fast internet connectivity, and stringent regulatory product approval framework continue to make North America and Europe a hotbed of opportunities for stakeholders. With an increased number of companies getting cloud based (SaaS) deployment of clinical trial solutions in developed regions, owing to smooth internet connectivity, the market continues to accelerate at a steady pace. Cloud based deployment of digitized solutions accounted for 64% of the overall spending in Europe.

As per the study North America eCOA, eSource & clinical trials spending has been witnessing a steady growth over the years, with the US spending expected to account for ~90% revenue share in the regional eCOA, eSource & clinical trials spending in 2018. In view of the manifold cost and processing benefits of digitization in clinical trials, a larger number of pharmaceutical companies, contract research organizations, and education & research institutions have shifted their focus on paperless approaches. Growing adoption of clinical trial solutions, which contributed ~40% revenue share in North America eCOA, eSource, and clinical trials market, continue to create a window of opportunities of growth for market players.

For More Insights https://www.biospace.com/article/parenteral-drugs-market-growing-on-the-back-of-rising-demand-for-monoclonal-antibodies-fact-mr

About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Categories
Pharmaceutical

Demand for Over The Couter Vitamins and Dietary Supplements Is Set to Expand at 6.7% CAGR By 2022

According to the recently conducted study by Fact.MR, the global demand for OTC vitamins and dietary supplements is set to expand at 6.7% CAGR during the forecast period (2017-2022) to surpass a valuation of US$ 97,688 Mn.

OTC vitamin and dietary supplement products. Over-the-counter (OTC) vitamins and dietary supplements are sold directly to consumers without any medical prescription. In many countries, OTC vitamins and dietary supplement products are regulated to ensure that they are effective and safe when used.

Drug regulatory bodies allow manufacturers to formulate vitamin ingredients or combination of ingredients that are well tolerated and do not pose any risk of side effects or reactions.  In recent years, the healthcare sector has witness exponential growth, which has reflected positively on the global market for OTC vitamins and dietary supplements.

Click HERE To get a SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.factmr.com/connectus/sample?flag=S&rep_id=61

Sales of such products have also increased in emerging countries such as China, India and Brazil primarily owing to the growing consumer awareness regarding the health benefits of such products. Convenience of direct purchase, cost-efficiency and growing trends of self-treatment are additional factors expected fuel the growth of the market. Moreover, manufacturers are also concentrating on developing advanced product formulations in order to improve their functionalities.

Need more information about Report Methodology? Click here-https://www.factmr.com/connectus/sample?flag=RM&rep_id=61

Market Segmentation

Global OTC Vitamins and Dietary Supplements Market Size and Forecast By Function

  • Immune Health
  • Digestive Health
  • Heart Health
  • Nutrition
  • Bone & Joint Health
  • General Well being
  • Weight Loss

Global OTC Vitamins and Dietary Supplements Market Size and Forecast By OTC Channel

  • Pharmacy
  • Drug Store
  • Modern Trade
  • Online Store
  • Other Retail

Global OTC Vitamins and Dietary Supplements Market Size and Forecast By Product Form

  • Liquid
  • Capsule
  • Tablet
  • Powder

Global OTC Vitamins and Dietary Supplements Market Size and Forecast By Region 

  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Full Access of this Exclusive Report is Available at-
https://www.factmr.com/checkout/61

Following insights from Fact.MR’s report on the global OTC vitamins and dietary supplements market will be crucial for market’s future growth

  • Among regions, North America is expected to remain one of the most lucrative market for OTC vitamins and dietary supplements between 2017 and 2022. The region currently commands for the highest value share of the global market as demand for various OTC drugs is on the rise particularly in the U.S. Asia Pacific excluding Japan (APEJ) is also projected to emerge as an attractive market for OTC vitamins and dietary supplements over 2022. In terms of revenue, the market in Europe is anticipated to command for over 31% share of the global market, by 2017-end.
  • On the basis of functions, OTC vitamins and dietary supplements are being used majorly for maintaining general well-being of the body. The general well-being segment accounts for a large percentage of the overall market revenue.
  • In 2017 and beyond, pharmacies will continue to be the top OCT channel for sales of OTC vitamin products including capsules and tablets. Over one-fourth revenue share of the global market is currently captured by the pharmacy OTC channel segment. Though, this OTC channel segment is expected to lose a small fraction of its revenue share over 2020, mainly due to emergence of new OCT channels such online retail and modern trade.
  • Sales of capsule based OTC vitamins and dietary supplements will continue to remain strong during the forecast period. By 2022-end, nearly US$ 32,891 Mn worth capsules are estimated to be sold across the globe.

For More Insights
https://www.biospace.com/article/implementation-of-novel-methods-for-active-pharmaceutical-ingredients-production-driving-contract-pharmaceutical-fermentation-services-market-fact-mr/

OTC vitamins and dietary supplements market include

  • Koninklijke DSM N.V.
  • Reckitt Benckiser LLC
  • Otsuka Holdings Co. Ltd.
  • CSPC Pharmaceutical Group Limited
  • Sanofi S.A.
  • Atrium Innovations Inc.
  • E. I. du Pont de Nemours and Co.
  • Bactolac Pharmaceutical Inc.
  • Dil Limited.
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Lonza Group Ltd.

About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Categories
Pharmaceutical

Over US$ 390 Mn Worth of Vocal Biomarker are Envisaged to be Sold Across the Globe by 2027-end

According to a recent research analysis, sound vibrations, which were employed as therapeutic healing for mental health conditions, are now witnessing application into various disease diagnostics including psychiatric and cardiovascular ailments. Post-successful execution of clinical trials, HIPAA-compliant vocal biomarkers are set to serve as effective alternatives to currently available disease diagnostic systems such as CT scan, MRI and X-ray.

Prominent voice-based companies such as IBM Corporation, Cogito Corporation, Audio Profiling, Sonde Health, and Beyond Verbal are focusing on sampling data for providing accurate results. For example – Beyond Verbal has been taking immense research efforts on vocal biomarkers and has compiled over 2.5 Mn samples of voice in more than 40 different languages.

Click HERE To get a SAMPLE  (Including Full TOC, Table & Figures) at
https://www.factmr.com/connectus/sample?flag=S&rep_id=719

Prominent voice-based companies such as IBM Corporation, Cogito Corporation, Audio Profiling, Sonde Health, and Beyond Verbal are focusing on sampling data for providing accurate results. For example – Beyond Verbal has been taking immense research efforts on vocal biomarkers and has compiled over 2.5 Mn samples of voice in more than 40 different languages.

vocal biomarker market

Site Management by CROs Essential for Ensuring Vocal Biomarker Clinical Trails’ Success

Contract research organizations (CROs) are likely to spearhead the global vocal biomarker market, in terms of revenues as well as growth rate. Given the expanding range of voice-assistant, health-related applications, life sciences and healthcare organizations have commenced designing an array of scenarios to deploy voice assistant platforms in clinical trial settings. Integration of these platforms in the research for vocal biomarkers has the potential to address specific drawbacks in current clinical trial environment.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=719

Vocal Biomarker Market: Taxonomy and Segmentation Analysis

Region
  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA
Technique
  • Frequency
  • Amplitude
  • Error Rate
  • Vocal Rise Or Fall Time
  • Phonation Time
  • Voice Tremor
  • Pitch
  • Other Types
End User
  • Hospitals & Clinics
  • CROs
  • Academic and Research Center
  • Other End User
Indication
  • Psychiatric Disorders
  • Respiratory Disorders
  • Cardiovascular Disorders
  • Traumatic Brain Injury (TBI)
  • Neurological Disorders
  • Other Disorder

CROs are essential and play a key role in ensuring the clinical trials’ success through proper site management. Accurate level of site management & oversight prompts site to effectively recruit, train, and retain subjects, meanwhile ensuring overall management of subjects, protocol adherence, and regulatory compliance. CROs help in maintaining and improving the communication flow, thereby reducing protocol deviations & violations, and addressing data issues & queries. These benefits of CROs also effectively apply to quality and integrity of clinical trials apropos of vocal biomarkers.

Non-invasiveness of Vocal Biomarker in Psychiatric Disorder Diagnostics in Sync with Self-diagnosis’ Upward Trend

Sound vibrations have been employed as biomarkers for diagnosing psychiatric disorders such as depression and anxiety. Similar distinctive features, known as vocal biomarkers, have been recently discovered by scientists that might pose a massive influence on developing a diagnostic tool. Additionally, latest research analyses have greatly impacted application of vocal biomarkers in diagnosing psychiatric ailments ranging from stress to Parkinson’s disease.

Full Access of this Exclusive Report is Available at-
https://www.factmr.com/checkout/719

Unlike other conventional and minimally invasive technologies such as ECG and MRI, which are impracticable for remote health monitoring on account of their high costs, vocal biomarkers serve as non-invasive diagnostic tools that provide great ease to patients with psychiatric disorders. Moreover, these significant user-friendly tools fall perfectly in line with the upward trend of self-diagnosis, which in turn has considerably fuelled their demand across the globe. Psychiatric disorders are likely to remain the leading indication in the global vocal biomarker market, with revenues estimated to rake in approximately US$ 130 Mn by 2027-end.

North America Vocal Biomarker Market: Driven by Government Agencies’ Tie-ups with Voice-Related Companies

Robust healthcare infrastructure, and presence of well-funded research organizations equipped with cutting-edge technologies in North America have made the region a lucrative breeding place for vocal biomarkers. Tie-ups of the U.S. government agencies with voice-based companies and analysis researchers is a primary demand determinant for vocal biomarkers in the region across areas such as geriatrics and war-induced trauma. For example, the U.S. Army entered into a collaboration with researchers from MIT for developing voice-based detection system to diagnose brain injuries.

For More Insights 
https://www.biospace.com/article/global-lung-cancer-diagnostics-market-set-to-expand-at-7-3-percent-cagr-through-2021-fact-mr

Fact.MR’s report foresees the global market for vocal biomarker to reflect a staggering expansion in the period of forecast, 2018 to 2027. Over US$ 390 Mn worth of vocal biomarkers are envisaged to be sold across the globe by 2027-end.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Categories
Pharmaceutical

Demand for Gram-Negative Bacterial Sepsis to Soar with High Growth Observed In US : Report Fact.MR

Fact.MR’s revised sepsis diagnostics market study forecasts a healthy growth trajectory for FY 2021-22 and beyond, with the market expected to increase at a CAGR worth around 8% through 2031. Growth prospects were further underpinned amidst the coronavirus pandemic, attributed to the onset of pneumonia-induced sepsis and consequent fatalities.

According to the report, the market is expected to yield high short-term gains, generating over US$ 700 million in revenue by 2026. These are largely attributed to ongoing research & development initiatives amid a general upswing in ICU and hospital admission-induced sepsis amongst patients. Manufacturers are incorporating the latest automated technologies to ensure precision and timely diagnostics.

To remain ‘ahead’ of your competitors, request for a sample –

https://www.factmr.com/connectus/sample?flag=S&rep_id=391

Epidemiologically, an estimated 22 cases of childhood sepsis per 100,000 person-years and 2,202 cases of neonatal sepsis per 100,000 live births occur. This translates into 1.2 million cases of childhood sepsis annually. Most recent estimates attributed an adult prevalence rate of 19.4 million sepsis incidences, with over 5 million deaths. Hence, investments are underway to introduce highly sophisticated sepsis diagnostic approaches, which are expected to incline demand over the coming years.

“As the frequency of hospital admissions for various diseases increases, risk of developing sepsis during treatment is rising, prompting healthcare settings to incorporate sepsis diagnostics and detection systems, spurring heightened R&D to introduce new solutions,” comments a Fact.MR analyst.

Key Takeaways from Market Study

  • By product, kits & reagents to remain the most deployed sepsis diagnostic solutions
  • Automated sepsis diagnosis to acquire greater momentum, backed by key solutions launches by prominent manufacturers
  • By pathogen, gram positive bacterial sepsis diagnosis to acquire major momentum
  • By technology, microbiology testing is likely to tower over other approaches, with molecular diagnostics acquiring high momentum
  • Increasing regulatory approvals of key equipment by the Food & Drug Administration heightening U.S. sales prospects
  • The U.K. to experience high penetration amid rising government initiatives to rein in sepsis fatalities
  • Technological breakthroughs to widen growth prospects for the market in Germany
  • Dearth of institutional level preparedness to cope with sepsis patient deluge spurring adoption of advanced equipment across India

Have a Query? Connect to Research Analyst

https://www.factmr.com/connectus/sample?flag=AE&rep_id=391

global sepsis diagnostics market

Market Taxonomy

Product Type
  • Blood Culture Media
  • Instrument
  • Assays & Reagents
Method
  • Conventional Diagnostics
  • Automated Diagnostics
Pathogen
  • Gram-negative Bacterial Sepsis
  • Gram-positive Bacterial Sepsis
  • Fungal Sepsis
  • Other Pathogens
Technology
  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Other Technology

Full Access of this Report Is Available At

https://www.factmr.com/checkout/391

Competitive Landscape

The global sepsis diagnostics market is interspersed with the presence of a large number of diagnostic service providers, rendering it highly competitive in nature. Amongst all the expansion strategies deployed, offering technologically advanced solutions by virtue of conducting immense R&D remains the core objective.

  • For instance, Luminex Corporation, a pioneer in diagnostics testing, offers the VERIGENE® and VERIGENE® II Systems, specifically designed to target infections in the blood stream, respiratory tract and gastrointestinal tract. These systems use highly automated workflows, helping perform extraction, amplification, hybridization and detection, helping improve clinical outcomes by preventing the onset of sepsis.
  • Likewise, Abionic SA offers the abioSCOPE, a non-fluidic immunoassay technology, which was tested across 14 European hospitals on several hundred patients, with doctors confirming that in over 85% of the cases, sepsis detection was possible more than 24 hours prior as compared to standard care. The solution was approved for clinical trials across U.S. hospitals in 2020.
  • Abionic SA
  • Biomérieux SA
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quidel Corporation
  • Becton
  • Dickinson and Company
  • Luminex Corporation
  • Abbott Laboratories Inc.
  • Qiagen NV

For More Insights

https://www.accesswire.com/641064/Personal-Flotation-Devices-Sales-to-Improve-with-Increasing-Demand-for-Water-Sports-Recreational-Activities-FactMR

Find More Valuable Insights

Fact.MR, in its new offering, presents an unbiased analysis of the sepsis diagnostics market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of product (blood culture media, instruments, and assays & reagents), method (conventional diagnostics and automated diagnostics), pathogen (gram-negative bacterial species, gram-positive bacterial species, fungal species, and other pathogens), and technology (microbiology, molecular diagnostics, immunoassays and other technologies), across six major regions of the world (North America, Latin America, Europe, APEJ, Japan, and MEA).

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website: https://www.factmr.com
Categories
Pharmaceutical

Market Outlook of Laboratory Information Management Systems (LIMS) will Remain Pragmatic with a CAGR of Over 7% until 2031

Prolific developments in life sciences, characterized by rapid AI penetration, industry-wide proliferation of cloud technology, and possible therapeutic connotations of previously contraband substances such as marijuana are amongst some key developments that have led to the emergence of a trillion dollar global pharmaceutical industry in recent years. This has eventually led to swift automation of laboratory settings, providing credible stimulus to the global lab automation market, according to a recent report published by consulting firm Fact.MR.

According to the report, the market is poised to experience significant gains, posting a CAGR exceeding 7% through 2031. Increasing number of grants disbursed to facilitate advanced drug development & clinical diagnostic research is responsible for bulk of the market’s growth. For instance, the EU Commission, in March 2021, advanced a grant to eTheRNA Immunotherapies, to accelerate the development of a novel and potentially best-in-class therapeutic mRNA cancer vaccine to treat recurrent HPV16+ head and neck cancers. The grant amounted to € 6.9 million.

To remain ‘ahead’ of your competitors, request a sample
https://www.factmr.com/connectus/sample?flag=S&rep_id=5672

Growth prospects have further heightened since the onset of COVID-19, with healthcare providers scrambling to deploy precise and advanced diagnostic services, as well as accelerate drug and vaccine development. Consequently, overall healthcare spending rose to US$ 1.4 trillion, representing over 30% increase since 2015. Additionally, a host of government initiatives in key markets have greatly helped augment spending on lab automation, a trend likely to continue over the coming years.

Key Companies Profiled

  • Thermo Fisher Scientific
  • Agilent Technologies
  • PerkinElmer
  • Hudson Robotics
  • Qiagen NV
  • F. Hoffmann-La Roche Ltd.
  • Hamilton Robotics
  • Siemens Healthineers
  • Becton Dickinson and Company
  • Bio-Rad Laboratories

Key Takeaways from Market Study

  • By product, demand for integrated automated workstations to expand at a rapid pace
  • Biotechnology & pharmaceutical industry experiencing major uptake of lab automation systems
  • By application, drug discovery and clinical diagnostics to collectively capture a lucrative share
  • Voluminous biopharmaceuticals manufacturing to elevate lab automation deployment across the U.S.
  • The U.K. to generate fresh revenue ecosystems amid high reliance on in vitro diagnostics
  • Growing R&D initiatives by government and non-governmental entities bolstering France and Germany’s growth prospects
  • India and China to emerge as lucrative hotspots amid increasing need to offset asymmetries in efficient lab testing mechanisms

“Growing irregularities in quality diagnosis & drug development due to high error margins are prompting healthcare providers to invest in the most contemporary lab automation solutions, driving market growth,”comments a Fact.MR analyst.

Speak to Research Analyst
https://www.factmr.com/connectus/sample?flag=AE&rep_id=5672

lab automation market

Key Segments Covered

  • Product
    • Equipment
      • Automated Workstations
      • Automated Liquid Handling
      • Automated Integrated Workstations
      • Pipetting Systems
      • Reagent Dispensers
      • Microplate Washers
    • Microplate Readers
      • Multi-mode Microplate Readers
      • Single-mode Microplate Readers
    • Automated ELISA Systems
    • Automated Nucleic Acid Purification  Systems
    • Software & Informatics
      • Workstation/Unit Automation Software
      • Laboratory Information Management Systems (LIMS)
      • Electronic Laboratory Notebook
      • Scientific Data Management System
  • Application
    • Drug Discovery
    • Clinical Diagnostics
    • Genomics Solutions
    • Proteomics Solutions
  • End User
    • Biotechnology & Pharmaceutical Industries
    • Research & Academic Institutes
    • Hospitals & Diagnostic Laboratories
    • Forensic Laboratories
    • Environmental Testing Labs
    • Food & Beverage Industry
  • Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East & Africa

Full Access of this Report Is Available At
https://www.factmr.com/checkout/5672

Competitive Landscape

Thermo Fisher Scientific, PerkinElmer, Agilent Technologies, Hudson Robotics, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Hamilton Robotics, Bio-Rad Laboratories, bioMerieux SA, Becton Dickinson & Company, Qiagen NV, Danaher Corporation, and Hudson Robotics are some prominent lab automation equipment and software providers profiled in Fact.MR’s report.

  • With regard to solution offerings, Siemens Healthineers provides the SIMATIC SIPAT Process Analytical Technology, facilitating the right-first-time production via Quality by Design (QbD) transfer of previously downstream quality controls into the manufacturing process itself. The software helps healthcare settings become more flexible with regard to production expansion, new product launches, and entry into new markets.
  • Similarly, Bio-Rad Laboratories offers its CFX Automation System II, a robotic plate handler compatible with all CFX RT-PCR Detection Systems to enable walk-away, high throughput qPCR operation in a simplified format. This systems generates large volumes of data and rapid data analysis. It is ideally suited to meet the high throughput RT-PCR requirements of today’s drug discovery and screening workflows.

For More Insights
https://www.prnewswire.com/news-releases/waxes-and-polishes-remains-top-selling-automotive-aftermarket-appearance-chemicals-with-sales-growing-at-3-through-2031-concludes-factmr-301327989.html

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the global lab automation market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of product (equipment and software & informatics), application (drug discovery, clinical diagnostics, genomic solutions, and proteomics solutions), and end-user (biotechnology & pharmaceutical industries, research & academic institutes, hospitals & diagnostic laboratories, forensic laboratories, environmental testing labs, and food & beverage industry), across five major regions of the world.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Categories
Pharmaceutical

How has COVID-19 Spurred Demand for Pharmaceutical Waste Management: Check Latest Study

The demand for medical waste management is poised to expand steadily, growing at a CAGR of 5.1% across the forecast period (2020-2025).

As healthcare infrastructure has started to develop, the number of surgical procedures for treating various chronic and infectious diseases have also increased. This has necessitated the safe disposal of medical waste generated during the surgical process. Over the years, various governmental and non-governmental organizations have bolstered efforts to ensure the proper management of medical waste.

The Centers of Medicare and Medicaid Services (CMS) project that healthcare spending shall increase by 5.6% across the forecast period. As a result, healthcare settings have been outsourcing their medical waste management services to third parties, thus broadening the scope of the market. The ongoing coronavirus pandemic is also anticipated to leverage the need for proper medical waste disposal to avoid the spread of infection within healthcare settings.

To remain ‘ahead’ of your competitors, request a sample https://www.factmr.com/connectus/sample?flag=S&rep_id=4804

A detailed assessment of the medical waste management market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the medical waste management market along with their product portfolio enhances the reliability of this comprehensive research study.

Key Takeaways from the Medical Waste Management Market Study:

  • By nature, non-hazardous medical waste is anticipated to account for a major chunk of the medical waste management market. The segment is poised to capture a market share of nearly 70% across the forecast period.
  • By waste type, the infectious waste segment is expected to grow the fastest, at a CAGR of 6.0%. This is attributed to the growing prevalence of infectious diseases such as SARS, Hepatitis, Tuberculosis and influenza. However, the non-infectious segment shall remain dominant, owing to rising prevalence of chronic disorders in the wake of a rapidly aging population.
  • By waste generator, large quantity waste generators are poised to remain in the vanguard of the medical waste generators market. Hospitals constitute the major chunk of medical waste generators, owing to the large volume of surgical procedures happening in a day.
  • By service type, off-site waste management shall gain traction, attributed to stringent government regulations and increased burden of healthcare expenditure. Key healthcare settings have been outsourcing their waste management to outside parties.
  • Regionally, North America is set to dominate the market, capturing nearly 40% market share while Asia-Pacific is expected to be significantly leveraged. Stringent healthcare regulations are boosting medical waste management prospects in North America while a rapidly evolving healthcare infrastructure drives growth in the Asia-Pacific.

Speak To Research Analyst For Detailed Insights:  https://www.factmr.com/connectus/sample?flag=AE&rep_id=4804

Medical Waste Management: Market Segmentation

Fact.MR has studied the medical waste management market with detailed segmentation on the basis of nature of waste, type of waste, waste generator type, service type and region.

Nature of Waste

Type of Waste

Waste Generator Type

Service Type

Region
Non-hazardous Waste Sharps Large Quantity Waste Generators:

  • Hospitals (Public & Private)
  • Pharmaceutical & Biotechnology Companies
 On-site Waste Management North America
Hazardous Waste Infectious & Pathological Waste Mid & Small Quantity Waste Generators:

  • Clinics & Physicians’ Offices
  • Retail Pharmacy
  • Ambulatory Surgical Centers & Long-term Care Centers
  • Laboratories (Pathological & Diagnostic)
  • Academic & Research Institutions
  • Blood Banks
  • Others
 Off-site Waste Management Europe
Radioactive Waste Asia Pacific
Pharmaceutical Waste Latin America
Non-infectious Waste Middle East & Africa (MEA)

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

For critical insights on this market, request for methodology here https://www.factmr.com/connectus/sample?flag=RM&rep_id=4804

Medical Waste Management Market: Analysis on Market Size Evaluation

The medical waste management market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for medical waste management is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent medical waste management market segments, along with market attractiveness evaluation, has been incorporated in the report.

Medical Waste Management Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the medical waste management report, which have helped deliver projection on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the medical waste management market during the forecast period.

Country-specific valuation on demand for medical waste management has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value for emerging countries has also been included in the report.

For More Insights:
https://www.biospace.com/article/radiation-proctitis-treatment-market-to-grow-at-7-percent-cagr-high-demand-for-oral-treatment-options-boosts-growth-fact-mr/

Medical Waste Management Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading providers of medical waste management services along with their detailed profiles. Essential and up-to-date data information related to market performers, who are principally engaged in the provision of medical waste management services, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis of each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the medical waste management market. Prominent manufacturers with established market presence in the medical waste management market are Stericycle Waste Management, Inc., Sharps Compliance, Inc., CLEAN HARBORS, INC., US Ecology, Inc., Medical Waste Solutions and Veolia.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
Categories
Pharmaceutical

Demand for Opthalmic OTC Drugs Drugs Is Anticipated Grow at a of CAGR of 4.2% by 2025

The global ophthalmic drugs market is anticipated grow moderately, at a CAGR of 4.2% during the forecast period (2020-2025). Visual impairments have increased across the world, owing to a multitude of factors. Varying in degree, visual impairments are a global health concern, affecting individuals physically and psychologically.

It is estimated that around 25% of the American population will suffer from cataract by 2020 while diabetic retinopathy patients will rise by nearly 20%. As a consequence, the demand for ophthalmic drugs is increasing. Moreover, rising FDA approvals for different drugs, such as Shire’s Xiidra, a lymphocyte function associated antigen-1 (LFA-1) antagonist, are leveraging market prospects.

For More Insights Into The Market, Request a Sample of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=4799

Key Takeaways of Global Ophthalmic Drugs Market Study:

  • By disease indication, the retinal disorders segment is set to dominate the ophthalmic drugs market. A burgeoning pool of retinal disorder patients is projected to leverage the segment’s market share. It is estimated that the number of people afflicted by age-related macular degeneration (AMD) hall reach 288 million by 2040. Projected market share of retinal disorders segment is pegged at 4.7% in the forecast period.However, the glaucoma segment is set to soar in popularity. This is attributed to a rising pool of glaucoma patients and the presence of important glaucoma drug manufacturers such as Pfizer and Novartis. The glaucoma segment is set to grow staggeringly at a CAGR of 3.5%, capturing two-fifth of the market.
  • By therapeutic class, the anti-glaucoma drugs segment is prophesied to capture a major chunk of the global ophthalmic drugs market. This is attributed to increasing prevalence, higher inclination towards combination methods and rising initiatives for treatment penetration. Also, industrial focus on development of glaucoma treatment drugs shall leverage the segment’s growth. Anticipated CAGR for anti-glaucoma drugs is 3.3% and a market share of over two-fifths.
  • By product type, over-the-counter drugs (OTC) segment is anticipated to be the most attractive of the global ophthalmic drugs market. OTC drugs are suitable for the treatment of seasonal infections such as conjunctivitis and dry eyes. These drugs also offer relatively short duration treatment. The OTC drugs segment shall dominate the global ophthalmological drugs market, accounting for more than half of the total market share.
  • By distribution channel, independent pharmacies and drug stores are anticipated to expand rapidly at a CAGR of 4.8%, capturing a market share of more than half the total ophthalmological drugs market. The high growth rate is due to its convenience, security, electronic payment technology and a wide range of available medications and services.
  • By region, North America shall capture almost two-fifth of the global ophthalmological drugs market during the forecast period. This is attributed to high cost of prescription drugs and presence of key market players such as Novartis AG and F. Hoffmann- La Roche, Ltd. Asia-Pacific is anticipated to expand modestly at a CAGR of 4.9%, attributed to increase in funding for research and presence of key market players in the wake of a large patient pool.

Access Research Methodology Prepared By Experts – https://www.factmr.com/connectus/sample?flag=RM&rep_id=4799

global ophthalmic drugs market value and growth forecast by disease indication

Global Ophthalmic Drugs Market Segmentation

Fact.MR has studied the global ophthalmic drugs market with detailed segmentation on the basis of disease indication, therapeutic class, product type, distribution channels and regions.

Disease Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation
  • Retinal Disorders:
  • Wet AMD
  • Dry AMD
  • Diabetic Retinopathy
  • Others
  • Allergy
  • Uveitis
  • Others

Therapeutic Class

  • Anti-inflammatory Drugs:
  • NSAIDs
  • Steroids
  • Anti-infective Drugs:
  • Anti-fungal Drugs
  • Anti-bacterial Drugs
  • Others
  • Anti-glaucoma Drugs:
  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Combined Medication
  • Others
  • Anti-allergy Drugs
  • Anti-VEGF Drugs
  • Others

Product Type

  • Prescription Drugs
  • OTC Drugs

Distribution Channels

  • Hospital Pharmacies
  • Online Pharmacies
  • Independent Pharmacies & Drug Stores

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

Share Your Requirements & Get Customized Reports – https://www.factmr.com/connectus/sample?flag=RC&rep_id=4799

 

Following Questions Answers Covered in the Report are:

  • How will the global Opthalmic Drugs Market perform during the forecast period? What will be the market size in terms of value and volume?
  • Which segment will drive the global Opthalmic Drugs Market? Which regional market will show extensive growth in the future? What are the reasons?
  • How will the market dynamics change because of the impact of future market opportunities, restraints, and drivers?
  • What are the key strategies adopted by players to sustain themselves in the global Opthalmic Drugs Market?
  • How will these strategies influence the market growth and competition?

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM)
  • EU – (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
  • CIS & Russia
  • Japan
  • Asia Pacific Excluding Japan (Greater China, India, S. Korea, ASEAN Countries, Rest of APEJ)
  • Middle East and Africa (GCC Countries, Turkey, Iran, Israel, South Africa , Rest of MEA)

Get More Insights –http://www.globenewswire.com/en/news-release/2018/07/12/1536346/0/en/Global-Automotive-Actuators-Market-Projected-to-Reach-US-19-801-6-million-value-by-2022-end.html

The Report Covers Exhaustive Analysis On:

  • Market Segments
  • Market Dynamics
  • Market Size & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website: https://www.factmr.com
Categories
Pharmaceutical

Sales of Nasal Drug Delivery Systems Is Anticipated to Register a CAGR Growth of 7% by 2025

The ongoing COVID-19 pandemic is set to leverage the global drug delivery systems market, expanding at a CAGR of 7.0% between 2020 and 2025. As the number of infections rise exponentially on a daily basis, healthcare providers are grappling with rising shortfalls in the provision of essential medical equipment such as respirators and ventilators.

As a result, key players in the industry have scaled up their production in order to meet shortages. The easing of nationwide lockdowns and lifting of travel restrictions is anticipated to regenerate production cycles and supply chains, thus restoring the supply of drug delivery systems. In addition, the utilization of drug delivery systems for gene therapy will leverage the global drug delivery systems market.

For detailed insights on enhancing your product footprint, request a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4768

The ongoing COVID-19 pandemic is set to leverage the global drug delivery systems market, expanding at a CAGR 7%.

between 2020 and 2025. As the number of infections rise exponentially on a daily basis, healthcare providers are grappling with rising shortfalls in the provision of essential medical equipment such as respirators and ventilators.

As a result, key players in the industry have scaled up their production in order to meet shortages. The easing of nationwide lockdowns and lifting of travel restrictions is anticipated to regenerate production cycles and supply chains, thus restoring the supply of drug delivery systems. In addition, the utilization of drug delivery systems for gene therapy will leverage the global drug delivery systems market.

For comprehensive insights on this market adoption, ask an analyst here- https://www.factmr.com/connectus/sample?flag=AE&rep_id=4768

global drug delivery systems market 01

Global Drug Delivery Systems: Market Segmentation

Fact.MR has studied the global drug delivery systems market with detailed segmentation on the basis of delivery system, route of administration, application and region.

Delivery System

  • Intra Uterine Implants
  • Pro-drug Implants
  • Polymeric Drug Delivery
  • Targeted Drug Delivery

Route of Administration

  • Oral
  • Injectable
  • Inhalation
  • Transdermal
  • Ocular
  • Nasal
  • Topical

Application

  • Infectious Disease
  • Oncology
  • Ophthalmology
  • Urology
  • Diabetes
  • CNS
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Takeaways of Global Drug Delivery Systems Market Study:

By delivery type, targeted drug delivery shall grow at a CAGR of 6.8%, accounting for almost half of the global drug delivery systems market. However, polymeric drug delivery is expected to grow the fastest at the rate of 7.3% during the forecast period. Use of nanotechnology and localized drug delivery are key growth drivers for both segments.
By application, the oncology segment shall expand the fastest at a CAGR of 7.5% while the CNS segment shall grow at a CAGR of 6.9%. Rising prevalence of cancer and neurological disorders have boosted the demand for enhanced drug delivery devices, thus boosting the overall market share.

By route of administration, the injectables segment shall capture a major chunk of the global drug delivery systems market, constituting 44.6% market share. The oral segment is close behind, capturing nearly 2/5th of the global drug delivery systems market. Faster drug delivery at the affected site drives the growth of the injectables segment while advancements in oral drug formulations such as solid lipid nanoparticles shall drive the growth of the oral drugs segment.
By region, North America shall dominate the global drug delivery systems market, capturing nearly 40% of the market. At the same time, Asia-Pacific shall expand the fastest, at a CAGR of 7.8% across the forecast period. Increasing prevalence of acute chronic infections, introduction of advanced drug delivery devices and systems and favorable reimbursement policies for key players shall drive growth in both regions.

“Introduction of nanotechnology, coupled with three-dimensional printing and strengthening of existing and new drugs are poised to act as important growth stimulators of the global drug delivery systems market. Key manufacturers are exploiting the available opportunities to consolidate their foothold within the market,” concludes a Fact.MR analyst.

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4768

Presence of Several Global & Local Market Players to Heat up Market Competition:

The global drug delivery systems market is characterized by the presence of a large number of global and local manufacturers. Prominent players include, but are not limited to, the following: Novartis AG, Pfizer, Inc., Baxter International, Inc., Bayer AG Boston Scientific Corporation, Johnson and Johnson Services, Inc., Amgen, Inc., and F. Hoffmann La-Roche Ltd. Development of new drug delivery systems and addressing anomalies among existing ones are important expansion strategies adopted by the important market players.

For instance, Novartis AG has acquired a patent to develop thermogelling peptide delivery systems in February 2020. In addition, the company currently offers the Binocrit and ZYKADIA drugs for treating symptomatic anemia associated with renal failure and treatment of non-small lung cancer. Pfizer, Inc., another prominent market player, provides the iSecure, ABBOJECT and CARPUJECT syringe systems. Additionally, it also offers IV drug delivery systems such as the ADD-Vantage ADDaptor delivery system.

For More Insights: https://www.biospace.com/article/increased-healthcare-spending-and-technological-advancements-are-shaping-future-of-waldenstrom-macroglobulinemia-market-finds-fact-mr/

Looking for more information?

The research study on the global drug delivery systems market by Fact.MR incorporates an unbiased assessment of key factors and trends responsible for shaping the landscape of the global drug delivery systems market over 2020-2025. It includes a detailed assessment of key parameters that are anticipated to exert influence during 2020-2026. Market statistics have been presented on the basis of delivery system (intra-uterine implants, pro-drug implants, polymeric drug delivery, and targeted drug delivery), route of administration (oral, injectable, inhalation, transdermal, ocular, nasal and topical) and application (infectious disease, oncology, ophthalmology, urology, diabetes, CNS and others) across five major regions.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com